Effect of renin-angiotensin system inhibition on cardiac structure and function and exercise capacity in heart failure with preserved ejection fraction: a meta-analysis of randomized controlled trials-Reference-Cited by-同舟云学术

Effect of renin-angiotensin system inhibition on cardiac structure and function and exercise capacity in heart failure with preserved ejection fraction: a meta-analysis of randomized controlled trials

Published:2020-06-19 Issue:6 Volume:26 Page:1477-1484
ISSN:1382-4147
Container-title:Heart Failure Reviews
language:en
Short-container-title:Heart Fail Rev

Author:

Fukuta Hidekatsu^ORCID,Goto Toshihiko,Wakami Kazuaki,Kamiya Takeshi,Ohte Nobuyuki

Publisher

Springer Science and Business Media LLC

Subject

Cardiology and Cardiovascular Medicine

Link

https://link.springer.com/content/pdf/10.1007/s10741-020-09969-1.pdf

Reference40 articles.

1. Vasan RS, Larson MG, Benjamin EJ, Evans JC, Reiss CK, Levy D (1999) Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. J Am Coll Cardiol. 33:1948–1955

2. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM (2006) Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 355:251–259

3. Tsuchihashi-Makaya M, Hamaguchi S, Kinugawa S, Yokota T, Goto D, Yokoshiki H, Kato N, Takeshita A, Tsutsui H (2009) Characteristics and outcomes of hospitalized patients with heart failure and reduced vs preserved ejection fraction. Report from the Japanese Cardiac Registry Of Heart Failure in Cardiology (JCARE-CARD). Circ J. 73:1893–1900

4. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J (2003) Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 362:777–781

5. Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A (2008) Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 359:2456–2467

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Beyond weight loss: the potential of glucagon-like peptide-1 receptor agonists for treating heart failure with preserved ejection fraction;Heart Failure Reviews;2024-09-13

2. Effects of calcium channel blockers in patients with heart failure with preserved ejection fraction: A protocol for systematic review and meta-analysis;PLOS ONE;2024-08-19

3. Effect of low blood pressure on prognosis of acute heart failure;Scientific Reports;2024-07-06

4. Cardiovascular Disease and Exercise: From Molecular Mechanisms to Clinical Applications;Journal of Clinical Medicine;2022-12-19

5. 3-Month Enalapril Treatment in Pediatric Fontan Patients With Moderate to Good Systolic Ventricular Function;The American Journal of Cardiology;2022-01